The latest addition to the tools for precision genome editing is the RNA-guided CRISPR/Cas system, an adaptive natural defense mechanism presented in bacteria and archaea against invading genetic elements. The type II CRISPR/Cas mechanism is a three-component system in which a short CRISPR RNA (crRNA), complexed with a transactivating crRNA (tracrRNA) and a Cas9 nuclease, hybridizes to a 20 bp target sequence, resulting in cleavage that destroys foreign DNA. Research has demonstrated that the Cas9 enzyme, together with a dual-tracrRNA: crRNA RNA chimera, named single-guided RNA (sgRNA), can generate site-specific double-strand break (DSB) in vitro. Another advantage of the CRISPR/Cas system is that it can be used for multiplexing by simultaneous delivery of multiple sgRNAs targeting different loci, which provides the possibility for genome-wide screenings.
Fig.1 CRISPR/Cas genome editors. (Lim & Kim, 2022)
According to the design and implementation of site-specific nuclease technologies, scientists in CD BioGlyco are committing to developing personalized therapies through classical and modern approaches. We provide transcription activator-like effector CRISPR/Cas systems services to our clients all over the world. Our services enable researchers to delete, insert, and correct any gene in a diverse range of cell types and organisms. The services we provide include but are not limited to:
Fig.2 Example of CRISPR/Cas-based glycogene knockout technology. (CD BioGlyco)
CD BioGlyco provides efficient and accurate Glycogene Editing Services for clients worldwide. If you have glycogene editing projects in hand, please feel free to contact us for more information.
Reference: